Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders

Details for Australian Patent Application No. 2004288716 (hide)

Owner Celgene Corporation

Inventors Zeldis, Jerome B.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004288716

PCT Pub. Number WO2005/046318

Priority 60/518,600 06.11.03 US

Filing date 4 November 2004

Wipo publication date 26 May 2005

International Classifications

A61K 38/20 (2006.01) Medicinal preparations containing peptides - Interleukins

A61K 31/00 (2006.01)

A61K 31/4525 (2006.01)

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

8 June 2006 PCT application entered the National Phase

  PCT publication WO2005/046318 Priority application(s): WO2005/046318

27 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004288717-Immunosorbent blood tests for assessing paroxysmal cerebral discharges

2004288715-Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders